Several brokerages have updated their recommendations and price targets on shares of Sanofi (NASDAQ: SNY) in the last few weeks:
- 11/17/2026 – Sanofi was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
- 11/9/2026 – Sanofi was upgraded by BNP Paribas Exane from “neutral” to “outperform”. They now have a $57.00 price target on the stock.
- 11/7/2026 – Sanofi was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/2/2026 – Sanofi was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
- 10/9/2026 – Sanofi is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
- 10/8/2026 – Sanofi was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 10/5/2026 – Sanofi had its “buy” rating reaffirmed by Berenberg Bank.
- 10/3/2026 – Sanofi was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/1/2026 – Sanofi had its “buy” rating reaffirmed by Jefferies Financial Group.
- 10/1/2026 – Sanofi had its “neutral” rating reaffirmed by JPMorgan Chase & Co..
- 9/29/2026 – Sanofi had its “buy” rating reaffirmed by Deutsche Bank.
Sanofi Stock Performance
Shares of NASDAQ SNY traded down $1.34 during midday trading on Thursday, hitting $45.78. The company’s stock had a trading volume of 3,431,960 shares, compared to its average volume of 3,495,777. The stock has a fifty day moving average price of $42.94 and a 200 day moving average price of $44.40. Sanofi has a one year low of $39.07 and a one year high of $50.60. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $110.99 billion, a price-to-earnings ratio of 22.66, a P/E/G ratio of 1.30 and a beta of 0.31.
Sanofi (NASDAQ:SNY – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The company had revenue of $17.25 billion during the quarter, compared to the consensus estimate of $14.30 billion. During the same period last year, the firm earned $2.91 EPS. Sanofi’s revenue for the quarter was up 16.2% on a year-over-year basis. On average, research analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
See Also
- Five stocks we like better than Sanofi
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
